Crysvita 2020 U.S. PROMOTIONAL AUDIT REPORT

Published July 2021 • 26 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Crysvita through reportable promotional activity in 2020 to drive use within the Tumor-Induced Osteomalacia and X-linked Hypophosphatemia markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Ultragenyx’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Family Medicine, Endocrinology, Internal Medicine, Nephrology, and Rheumatology) and how does this compare to the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Crysvita throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Crysvita in 2020?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 1,900 paid interactions across 1,500 physicians made on behalf of Crysvita were carefully examined to support our analysis.